Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) - Drugs In Development, 2021

July 2021 | 550 pages | ID: P52EF91FAD38EN
Global Markets Direct

Abstracts

Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Polycythemia Vera Myelofibrosis - Drugs In Development, 2021, provides an overview of the Post-Polycythemia Vera Myelofibrosis (Oncology) pipeline landscape.

Post-Polycythemia Vera Myelofibrosis (PPV-MF) is a myeloproliferative blood cancer in which the bone marrow makes too many red blood cells. It may also result in the overproduction of white blood cells and platelets. Symptoms include heart attack, stroke, deep venous thrombosis, Headaches, lack of concentration and fatigue. The disease may be controlled by chemotherapy, transfusions, transplant and medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post-Polycythemia Vera Myelofibrosis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Post-Polycythemia Vera Myelofibrosis (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Polycythemia Vera Myelofibrosis (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Phase I stages are 1, 9, 20 and 11 respectively.

Post-Polycythemia Vera Myelofibrosis (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Polycythemia Vera Myelofibrosis (Oncology).
• The pipeline guide reviews pipeline therapeutics for Post-Polycythemia Vera Myelofibrosis (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Post-Polycythemia Vera Myelofibrosis (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Post-Polycythemia Vera Myelofibrosis (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Post-Polycythemia Vera Myelofibrosis (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Post-Polycythemia Vera Myelofibrosis (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Post-Polycythemia Vera Myelofibrosis (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Overview
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics Development
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics Assessment
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Companies Involved in Therapeutics Development
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Drug Profiles
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Dormant Projects
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Discontinued Products
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by AbbVie Inc, 2021
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Acceleron Pharma Inc, 2021
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Actuate Therapeutics Inc, 2021
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Bristol Myers Squibb Co, 2021
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Constellation Pharmaceuticals Inc, 2021
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by CTI BioPharma Corp, 2021
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by F. Hoffmann-La Roche Ltd, 2021
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Geron Corp, 2021
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Hangzhou East China Pharmaceutical Group Co Ltd, 2021
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Imago BioSciences Inc, 2021
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Incyte Corp, 2021
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Italfarmaco SpA, 2021
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by JW Pharmaceutical Corp, 2021
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Kartos Therapeutics Inc, 2021
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Karyopharm Therapeutics Inc, 2021
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Lynk Pharmaceutical Hangzhou Co Ltd, 2021
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by MEI Pharma Inc, 2021
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Merck & Co Inc, 2021
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Millennium Pharmaceuticals Inc, 2021
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Novartis AG, 2021
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by NS Pharma Inc, 2021
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Pharmaxis Ltd, 2021
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Rhizen Pharmaceuticals SA, 2021
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Samus Therapeutics Inc, 2021
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Sierra Oncology Inc, 2021
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Sino Biopharmaceutical Ltd, 2021
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Sumitomo Dainippon Pharma Oncology, Inc, 2021
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, 2021
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Telios Pharma Inc, 2021
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Dormant Projects, 2021
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), 2021
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021